Skip to content
XPR – Lifestyle Demo
Author:
Brii Biosciences Limited
Brii Bio Announces Topline End-of-Treatment Data from Phase 2b ENRICH and ENHANCE Studies for the Treatment of Chronic Hepatitis B
July 2, 2026
Brii Bio Presents Late-Breaking Data from Its Phase 2 ENSURE Study at EASL Congress 2026, Further Supporting the Potential Role of BRII-179 in Achieving Durable Immunological Control of HBV
May 27, 2026
Brii Bio Presents Cross-Study Analysis of Post-Treatment HBsAg Rebound at APASL 2026
April 26, 2026
Brii Biosciences Provides Corporate Updates and Reports Full Year 2025 Financial Results
March 19, 2026